Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.
Ciarka A, Kunc M, Popęda M, Łacko A, Radecka B, Braun M, Pikiel J, Litwiniuk M, Pogoda K, Iżycka-Świeszewska E, Zeller A, Niemira M, Pęksa R, Biernat W, Senkus E. Ciarka A, et al. Among authors: lacko a. Contemp Oncol (Pozn). 2024;28(1):75-83. doi: 10.5114/wo.2024.139375. Epub 2024 May 3. Contemp Oncol (Pozn). 2024. PMID: 38800535 Free PMC article.
The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx.
Jarząb M, Litwiniuk M, Innis P, Łacko A, Enderle G, Czartoryska-Arłukowicz B, Talerczyk M, Streb J, Wysocki P, Suchodolska G, Szymanowski B, Duchnowska R. Jarząb M, et al. Among authors: lacko a. Contemp Oncol (Pozn). 2024;28(3):245-252. doi: 10.5114/wo.2024.144222. Epub 2024 Oct 15. Contemp Oncol (Pozn). 2024. PMID: 39512534 Free PMC article.
Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study.
Püsküllüoğlu M, Pieniążek M, Las-Jankowska M, Streb J, Ziobro M, Pacholczak-Madej R, Kilian-Van Miegem P, Rudzińska A, Grela-Wojewoda A, Łacko A, Jarząb M, Polakiewicz-Gilowska A. Püsküllüoğlu M, et al. Among authors: lacko a. Oncol Ther. 2024 Dec;12(4):787-801. doi: 10.1007/s40487-024-00307-1. Epub 2024 Sep 27. Oncol Ther. 2024. PMID: 39331319 Free PMC article.
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. Hortobagyi GN, et al. Among authors: lacko a. Ann Oncol. 2024 Oct 21:S0923-7534(24)04064-X. doi: 10.1016/j.annonc.2024.10.015. Online ahead of print. Ann Oncol. 2024. PMID: 39442617 Free article.
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators. Balmaña J, et al. Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19. Breast Cancer Res Treat. 2024. PMID: 38112922 Free PMC article. Clinical Trial.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G; DESTINY-Breast06 Trial Investigators. Bardia A, et al. N Engl J Med. 2024 Dec 5;391(22):2110-2122. doi: 10.1056/NEJMoa2407086. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282896 Clinical Trial.
159 results